查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2071522

思覺失調症：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

Schizophrenia - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 154 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 預計義大利思覺失調症治療市場將從 3.04 億美元成長到 3.35 億美元，顯示市場將溫和擴張。
  • 以下因素正在推動市場成長：
  • 擴大長效注射藥物的使用
  • 擴大治療策略
  • 雖然患者人數穩定成長，但更長的治療週期和預防復發的策略支撐了市場規模。
  • 新型抗精神病藥物和數位/行為介入的持續創新有望塑造未來的市場動態。
  • 未來的成長取決於能夠解決負面症狀、認知障礙和提高藥物依從性的治療方法。

思覺失調症概述

思覺失調症是一種慢性、功能障礙性精神疾病，其特徵為陽性症狀（幻覺、妄想和言語混亂）和陰性症狀（社交退縮、動力減退和情感淡漠）。其病因複雜，涉及遺傳易感性、環境壓力以及多巴胺、麩胺酸和乙醯膽鹼通路失調。診斷基於臨床精神科評估，採用DSM-5-TR或ICD-11的標準。兩者都強調對症狀嚴重程度進行多維度評估，而非傳統的單一臨床亞型。治療需要終身的多學科護理，結合心理社會干預和先進的藥物治療。傳統的抗精神病藥物依賴多巴胺D2受體拮抗作用，而現代治療模式則優先使用新一代口服毒蕈鹼受體促效劑（如扎諾美林和托吡銨），以有效調節神經迴路並緩解症狀，且不會引起錐體外症狀或代謝副作用。此外，對於病情嚴重加重的患者，會採取急性期住院治療以確保安全。

主要亮點

  • 在美國，診斷率非常高，約有 95% 的病例被確診，這反映出臨床實踐中較高的意識和篩檢水準。
  • 大約 77% 的患者正在接受藥物治療（截至 2025 年），這表明診斷和接受治療之間存在很大的差距。
  • 在應對對長期功能有重大影響的負面和認知症狀方面，仍然存在未被滿足的需求。
  • 治療依從性仍然是一個重大挑戰，也是導致復發率和反覆住院的因素。
  • 為了提高藥物依從性並減輕疾病負擔，長效注射抗精神病藥物（LAI）的使用正在增加。

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興的治療方法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • LB Pharmaceuticals Inc.
  • Vanda Pharmaceuticals
  • Novartis Pharmaceuticals
  • AbbVie
  • Eli Lilly and Company
  • Otsuka Pharmaceutical Co., Ltd.
  • Anavex Life Sciences Corp.
  • Anxo Pharmaceutical Co., Ltd.
  • Qilu Pharmaceutical Co., Ltd.
  • Spinogenix
  • MapLight Therapeutics
  • Bristol-Myers Squibb
  • Boryung Pharmaceutical Co., Ltd
  • Click Therapeutics, Inc.
  • Merck Sharp &Dohme LLC
  • Hoffmann-La Roche
  • Celon Pharma SA
  • Boehringer Ingelheim
  • ACADIA Pharmaceuticals Inc.
  • Janssen-Cilag Ltd.
  • Intra-Cellular Therapies, Inc.
  • NeuShen Therapeutics
  • Newron Pharmaceuticals SPA
  • Alto Neuroscience
  • Alkermes, Inc.

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並正在接受藥物治療的患者族群。
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 目前主要療法－概述及關鍵意見領袖見解
  • 新興療法
  • 重點
  • 值得關注的後期新興療法—概述、市場上市預期和關鍵意見領袖見解
  • 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

  • 尚未滿足的主要需求及其透過新興療法實現的潛力。
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

Schizophrenia Market Outlook

Thelansis's "Schizophrenia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Schizophrenia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Schizophrenia Overview

Schizophrenia is a chronic, disabling psychiatric disorder characterized by positive symptoms (hallucinations, delusions, disorganized speech) and negative symptoms (social withdrawal, avolition, blunted affect). Its multifactorial etiology involves genetic vulnerability, environmental stressors, and dysregulation of dopamine, glutamate, and acetylcholine pathways. Diagnosis relies on clinical psychiatric assessment using DSM-5-TR or ICD-11 criteria, both of which emphasize dimensional symptom severity rather than historical, rigid clinical subtypes. Management requires lifelong, multidisciplinary care combining psychosocial interventions with advanced pharmacotherapy. While traditional antipsychotics rely on dopamine D2 receptor antagonism, the modern therapeutic paradigm preferentially deploys next-generation oral muscarinic receptor agonists (such as xanomeline-trospium) to effectively modulate circuits and alleviate symptoms without causing extrapyramidal or metabolic side effects, utilizing acute hospitalization to ensure safety during severe exacerbations.

Key Highlights

  • In the United States, diagnosis rates are high, with ~95% of cases identified, reflecting strong clinical awareness and screening.
  • Approximately 77% of patients receive drug treatment (2025), indicating a notable gap between diagnosis and treatment uptake.
  • Persistent unmet need exists in managing negative and cognitive symptoms, which significantly impact long-term functioning.
  • Treatment adherence remains a critical challenge, driving relapse rates and repeated hospitalizations.
  • Increasing adoption of long-acting injectable antipsychotics (LAIs) to improve compliance and reduce disease burden.

Market Overview

  • The Italy schizophrenia market is projected to grow from $304M to $335M, reflecting modest market expansion.
  • Market growth is driven by:
  • Increased uptake of long-acting injectable therapies
  • Expansion of maintenance treatment strategies
  • Despite stable patient population growth, market value is supported by chronic treatment duration and relapse prevention strategies.
  • Continued innovation in novel antipsychotics and digital/behavioral interventions is expected to shape future market dynamics.
  • Future growth will depend on therapies addressing negative symptoms, cognitive deficits, and adherence improvement.

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • LB Pharmaceuticals Inc.
  • Vanda Pharmaceuticals
  • Novartis Pharmaceuticals
  • AbbVie
  • Eli Lilly and Company
  • Otsuka Pharmaceutical Co., Ltd.
  • Anavex Life Sciences Corp.
  • Anxo Pharmaceutical Co., Ltd.
  • Qilu Pharmaceutical Co., Ltd.
  • Spinogenix
  • MapLight Therapeutics
  • Bristol-Myers Squibb
  • Boryung Pharmaceutical Co., Ltd
  • Click Therapeutics, Inc.
  • Merck Sharp & Dohme LLC
  • Hoffmann-La Roche
  • Celon Pharma SA
  • Boehringer Ingelheim
  • ACADIA Pharmaceuticals Inc.
  • Janssen-Cilag Ltd.
  • Intra-Cellular Therapies, Inc.
  • NeuShen Therapeutics
  • Newron Pharmaceuticals SPA
  • Alto Neuroscience
  • Alkermes, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)